SELLAS Life Sciences Proposes $150 Million Stock Offering After Phase 3 REGAL Data
· 6 sources
SELLAS Life Sciences (SLS) plans a $150 million public offering after its Phase 3 REGAL trial met its survival goal, according to several outlets.
What happened
SELLAS Life Sciences (NASDAQ: SLS) announced a proposed underwritten public offering of common stock worth $150 million, according to Investing.com, MarketScreener, The Manila Times and TokenPost. The announcement followed results from the company's Phase 3 REGAL trial.
Kalkine reports that the trial reached its survival goal, and that the shares surged during the session. Stock Titan notes survival figures of 24 months versus 14.7 months in the trial.
Stock Titan adds that the underwriters have a 30-day option to buy up to $22.5 million of additional stock. The expected proceeds are earmarked for uses that include clinical development and potential commercialization.
Context
Companies in clinical-stage biotechnology often raise capital through public offerings after reporting trial results, which can increase the number of shares outstanding.
Why it matters
The offering shows how SELLAS plans to fund its next steps after the trial data, and it may affect the company's share count and financing position.
Stocks in this story
Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.
39%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $11.63 and $21.50; 9 in 10, between $6.74 and $37.08.
Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.
Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer
ATLAS Signals
ATLAS Signals, every week
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy